Latest glioblastoma multiforme Stories
(Ivanhoe Newswire) – Glioblastoma is the most common brain malignancy and one of the most lethal of all cancers, killing most victims within 12-15 months of diagnosis. It is also one of the most chemotherapy-radiation resistant cancers. Researchers found that by blocking brain cancer cells from getting large amounts of cholesterol they could provide a new strategy to battle glioblastoma, according to this study. The study, done in cells lines, mouse models and analysis of tissue from...
Glioblastoma is among the most lethal cancers, but scientists have uncovered a novel growth mechanism that suggests patients with glioblastoma could be treated with cholesterol-lowering agents, according to a study published in Cancer Discovery, the newest journal of the American Association for Cancer Research. Lead researcher Paul Mischel, M.D., Lya and Harrison Latta professor of pathology and laboratory medicine, and professor of molecular and medical pharmacology at the David Geffen...
A new study suggests that blocking cancer cells' access to cholesterol may offer a new strategy for treating glioblastoma, the most common and deadly form of brain cancer, and perhaps other malignancies. The potential treatment could be appropriate for tumors with a hyperactive PI3K signaling pathway, which accounts for up to 90 percent of glioblastomas cases. Researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove...
Blocking the uptake of large amounts of cholesterol into brain cancer cells could provide a new strategy to battle glioblastoma, one of the most deadly malignancies, researchers at UCLA's Jonsson Comprehensive Cancer Center have found. The study, done in cells lines, mouse models and analysis of tissue from brain cancer patients, uncovered a novel mechanism by which the most commonly activated oncogene, the mutated epidermal growth factor receptor (EGFR), overcomes normal cell regulatory...
New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures. The research is published in the August 31, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology. "Despite some limitations, our results suggest that the choice of seizure medications in brain tumor patients should be carefully considered as it may...
New imaging device enables scientists to see tumor cells traveling in the brain For the first time, scientists can see pathways to stop a deadly brain cancer in its tracks. Researchers at Case Western Reserve University School of Medicine have imaged individual cancer cells and the routes they travel as the tumor spreads. The researchers used a novel cryo-imaging technique to obtain the unprecedented look at a mouse model of glioblastoma multiforme, a particularly aggressive cancer that...
SEATTLE, Aug. 18, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC and MTA: CTIC) announced that enrollment has opened for a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX) and radiation ("RT") to the combination of temozolomide ("TMZ") and RT for patients with newly diagnosed glioblastoma, a high-grade malignant brain tumor. The objectives of the study are to determine if OPAXIO and RT improve progression free survival...
A clinical trial has shown that a form of gene therapy is safe for treating a deadly form of brain cancer, even when combined with radiation therapy.The phase 1b trial was conducted at the Ohio State University Comprehensive Cancer Center "“ Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC "“ James) and at Methodist at Hospital in Houston, TX.The novel treatment uses an adenovirus vector called AdV-tk. The vector is taken up by cancer cells where it...
BETHESDA, Md., Aug. 4, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the Company's ongoing clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company also announced that a substantial number of additional sites are in process. With the 12 sites already...
A single compound with dual function "“ the ability to deliver a diagnostic and therapeutic agent "“ may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.Glioblastomas are the most common and aggressive brain tumor in humans, with a high rate of relapse. These tumor cells often extend beyond the well-defined tumor margins making it extremely difficult for clinicians and...
